Epithelial ovarian cancer: focus on targeted therapy.
Epithelial ovarian cancer: focus on targeted therapy.
复制标题
DOI：
10.1155/2010/171425
复制
发表时间：
2010
影响因子：
--
通讯作者：
Chi DS
中科院分区：
文献类型：
--
作者：
Markman M;Sehouli J;Levenback CF;Chi DS
在过去的五年里，卵巢癌引起了临床癌症研究人员的极大兴趣，因为它是所有实体瘤中对化学最敏感的肿瘤之一[1]。不幸的是，尽管这种恶性肿瘤的化疗管理取得了进展，但绝大多数患者最终由于疾病过程并发症的直接结果而复发、进展，并最终死亡。因此，迫切需要找到可能对卵巢癌自然史产生有利影响的新药物。近年来，癌症研究界特别关注发现并随后开发临床活性药物，这些药物能够专门针对特定肿瘤类型（例如卵巢癌）甚至特定患有该类型癌症的患者的相关生物途径（所谓的“个性化医疗”）。尽管最近在同行评审的医学文献中报道了许多令人兴奋的进展，但卵巢癌这一领域的研究仍处于早期阶段，这些进展表明这种新型通用药物很快将成为治疗这种疑难恶性肿瘤的“护理标准”的重要组成部分。在本期特刊中，来自世界各地的研究人员通过总结一些重要的进展为该文献做出了贡献。在本期特刊的论文中，首先讨论了手术细胞减灭术在恶性肿瘤中的作用，然后概述了复发性卵巢癌的治疗以及特定卵巢癌亚型中分子异常的相关性。
Over the past five decades ovarian cancer has been of considerable interest to clinical cancer investigators due to the fact that it is among the most chemosensitive of all solid tumors [1]. Unfortunately, despite the advances in the chemotherapeutic management of this malignancy, the large majority of patients ultimately recur, progress, and ultimately die as a direct result of complications of the disease process. Thus, there is a critical need to find novel agents that may favorably impact the natural history of ovarian cancer. In recent years there has been a particular focus in the cancer research community to discover and subsequently develop clinically active drugs that are capable of specifically targeting biological pathways relevant in a particular tumor type (eg, ovarian cancer) and even within a specific patient with that type of cancer (so-called,“personalized medicine”). Research in this arena in ovarian cancer remains in its early stages although a number of quite exciting developments have recently been reported in the peer-reviewed medical literature that suggest the realistic potential that this novel general class of drugs will soon become important components of “standard-of-care” in the management of this difficult malignancy.In this special issue, investigators from around the world have contributed to this literature by summarizing a number of important developments. In the papers of this special issue, an initial discussion of the role of surgical cytoreduction in the malignancy is followed by an overview of the management of recurrent ovarian cancer and the relevance of molecular abnormalities in specific ovarian cancer subtypes.